Kim Witczak has crusaded for informed consent in antidepressants for two decades and more recently joined with Marty Makary, ...

Pfizer’s multi-year lows reflect headwinds, lack of catalysts, and fading appeal to both growth and defensive investors. Read ...

Happily for investors, Pfizer is generating enough cash flow to cover its dividend. In 2024, it paid $9.5 billion in ...

Pfizer's (NYSE: PFE) shares have been southbound for the better part of three years, partly because it was unable to repeat its incredible financial performance during the early pandemic years. At ...

Despite the challenges, including what CSL CEO Paul McKenzie has described as a fragmented U.S. healthcare system, the blood ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

You may know 175-year-old pharmaceutical company Pfizer (NYSE: PFE) best for its COVID-19 vaccine, but investors have long ...

Pfizer is officially bidding adieu to its sprawling research site in San Diego as it readjusts its local footprint and moves into a new site. | The company is moving its oncology R&D digs in San Diego ...

Pfizer’s PFE stock hit a new 52-week low of $20.92 on Wednesday but recovered thereafter and closed at $22.49 Though the ...

Pfizer sold the five-building facility on Science Center Drive in Torrey Pines to BioMed Realty, a San Diego-based firm owned ...

Shares in many large drugmakers initially fell Wednesday on the president's threat, only to rebound later when he announced a ...